Abstract
Standard treatment of moderate to severe persistent asthma is based on anti-inflammatory treatment with inhaled corticosteroids combined with long-acting bronchodilators and leukotriene antagonists. Over the last two decades, studies have been dramatically growing with the use of biological treatment.
Accepted within the EU are now four molecules with selective approaches to allergic and eosinophilic airway inflammation. In severe asthmatics with frequent exacerbations of the use of biologic therapy that targets the pathway of interleukin 5 (mepolizumab, reslizumab, benralizumab) or immunoglobulin E (omalizumab), it significantly improves asthma control.
New approaches to the treatment of severe asthma require an expert judgment in the fate of asthma because the molecules overlap some effects. At the same time, some molecules also solve the "Th2 high asthma" syndrome - atopic eczema, nasal polyposis, current biomarkers and the use of omics technologies to improve the indication of this costly treatment.